Upregulation and downregulation of gene expression or selective editing of key genes known to be modified in PD, such as PRKN, GDNF, PINK1, and AADC (aromatic L-amino acid decarboxylase), can be used to correct defects in the molecular pathways related to PD [113]. This evidence concerns the gene GDNF and Parkinson disease.